Immunomodulatory Effect of the Topical Ophthalmic Janus Kinase Inhibitor Tofacitinib (CP-690,550) in Patients with Dry Eye Disease

Huang, Jing-Feng; Yafawi, Rolla; Zhang, Min; McDowell, Michael T.; Rittenhouse, Kay D.; Sace, Frederick; Liew, Shiao Hui Melissa; Cooper, Scott; Pickering, Eve H.

doi:10.1016/j.ophtha.2012.03.017

Cited by 66 publications

(35 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…45 Results suggest that left untreated ocular surface inflammation in certain patients with irritation symptoms and clinically evident ocular surface disease associated with tear dysfunction may actually worsen or show intermittent exacerbation over a 6-month period. 45 CD11c is a dendritic cell marker. 46 CD11c-positive dendritic cells are the resident antigen-presenting cells in the conjunctival epithelium.…”

Section: Discussionmentioning

confidence: 91%

Long-term Supplementation With n-6 and n-3 PUFAs Improves Moderate-to-Severe Keratoconjunctivitis Sicca

Sheppard

Singh

McClellan

et al. 2013

Cornea

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 91%

Long-term Supplementation With n-6 and n-3 PUFAs Improves Moderate-to-Severe Keratoconjunctivitis Sicca

Sheppard

Singh

McClellan

et al. 2013

Cornea

View full text Add to dashboard Cite

show abstract

“…Certain inflammatory markers, such as class II human leukocyte antigen have shown to be sensitive efficacy parameters in therapeutic trials, and they may prove to be less variable than ocular surface dye staining. 44,56 …”

Section: Introductionmentioning

confidence: 99%

New Testing Options for Diagnosing and Grading Dry Eye Disease

Foulks

Pflugfelder

2014

American Journal of Ophthalmology

View full text Add to dashboard Cite

PURPOSE To describe new options for diagnosis and severity grading of dry eye disease DESIGN Perspective on technological advancements to identify tear dysfunction and their value in diagnosing and grading dry eye disease. METHODS Evidence is presented on new and evolving technologies to measure tear stability, composition and meniscus height and their role in dry eye diagnosis and therapeutic efficacy grading is assessed. RESULTS Evolving concepts regarding pathogenesis and new technologies to evaluate the tears and ocular surface have improved the ability to diagnose, classify and grade the severity of dry eye disease. New technologies include noninvasive imaging of tear stability and tear meniscus height as a measure of tear volume and tear composition (osmolarity, lacrimal factors, inflammatory mediators, growth and differentiation factors). Approved tests, such as tear osmolarity and tear imaging, are being integrated into clinical practice and may eventually supplant certain traditional tests that have greater variability and less sensitivity. Other tests, such as molecular assays of tears and conjunctival cells are currently being used in studies investigating pathogenesis and therapeutic mechanism of action. They may eventually translate to routine clinical practice. CONCLUSIONS New technologies have emerged that can noninvasively evaluate the tears and measure disease-associated compositional changes. These tests are being integrated into clinical practice and therapeutic trials for diagnosis, classification and severity grading of dry eye disease.

show abstract

“…As a small molecule, it could theoretically be delivered topically for the treatment of uveitis and has been tested topically for the treatment of dry eye. 20 Whether it will inhibit or exacerbate uveitis when given systemically versus locally remains to be determined given the pleiotropic effects that IFNγ has in uveitis.…”

Section: Datamentioning

confidence: 99%